For a subset of the youngest patients with the brain tumor medulloblastoma, less aggressive therapy was associated with better long-term survival.
The protein called BOK offers another target for drugs to selectively trigger apoptosis.
St. Jude is partnering with WHO to develop strategies that strengthen the global resources, organization and planning needed to identify and treat pediatric cancer.
Researchers created the first genetic screening guidelines for medulloblastoma patients after identifying gene variations that make carriers susceptible.
Using combination therapy for flu, a new class of drug offers potential for multi-drug therapy and possibly improved influenza-fighting drugs.
A family’s history of childhood leukemia leads to the discovery of a fourth gene (IKZF1) that predisposes carriers to pediatric acute lymphoblastic leukemia.
St. Jude Cloud, largest public repository of pediatric cancer genomics data, launches for researchers worldwide
St. Jude to offer next-generation sequencing data and analysis tools to accelerate research and cures for life-threatening pediatric diseases.
Explore research and resources by St. Jude at the annual meeting of the American Association for Cancer Research (AACR) in Chicago.
What explains cognitive problems in childhood leukemia survivors treated with chemotherapy alone? The answer may be a surprise.
Read about the molecule (IRF8) that is essential for launching an optimal immune response to Salmonella, Pseudomonas and related bacteria.
Explore more research news
More Research News
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Courageous patients. Resolute doctors. Caring staff. Inventive scientists. Their voices come alive in Promise magazine.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.